Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Mingyang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9121-2591; OpenAlex author ID A5067677121, A5123350048. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2024: 1 paper · 2025: 3 papers · 2026: 4 papers

Papers 8

  1. Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. Last author DOI 10.1016/j.canlet.2026.218331↗
  2. Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: From mechanisms to clinical translation. Last author DOI 10.1016/j.canlet.2026.218391↗
  3. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  4. From static snapshots to spatial evolution: reconstructing the malignant progression from IPMN to invasive PDAC. Last author DOI 10.1016/j.pan.2026.01.004↗
  5. Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2025.217523↗
  6. N-acetyltransferase 10 Promotes Pancreatic Cancer Progression Through ZEB1/MT1-MMP Axis. Last author DOI 10.1097/mpa.0000000000002492↗
  7. ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Last author DOI 10.1172/jci195970↗
  8. Retraction Note: ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experi… Co-author DOI 10.1007/s10142-024-01373-4↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haoran Qi · 4 shared papers, 2025–2026 · strength 1.38
  2. Yumeng Hu · 4 shared papers, 2025–2026 · strength 0.98
  3. Shaobo Zhang · 3 shared papers, 2025 · strength 0.71
  4. Fangxia Wang · 3 shared papers, 2025 · strength 0.71
  5. Shaobo Zhang · 2 shared papers, 2026 · strength 0.66
  6. He Jiang · 1 shared paper, 2026 · strength 0.50
  7. Xiaohao Zheng · 1 shared paper, 2024 · strength 0.31
  8. Chengfeng Wang · 1 shared paper, 2024 · strength 0.31
  9. Binghe Xu · 1 shared paper, 2026 · strength 0.27
  10. Zhijun Zhou · 1 shared paper, 2025 · strength 0.22
  11. Min Li · 1 shared paper, 2025 · strength 0.22
  12. Wenming Wu · 1 shared paper, 2025 · strength 0.22
  13. Zhihua Liu · 1 shared paper, 2025 · strength 0.22
  14. Yongxing Du · 1 shared paper, 2025 · strength 0.22
  15. Jingyong Xu · 1 shared paper, 2025 · strength 0.22
  16. Meilian Zhuo · 1 shared paper, 2026 · strength 0.21
  17. Xianlin Han · 1 shared paper, 2026 · strength 0.21
  18. Ruizhe He · 1 shared paper, 2026 · strength 0.21
  19. Mo Chen · 1 shared paper, 2026 · strength 0.21
  20. Junya Peng · 1 shared paper, 2026 · strength 0.21
  21. Menghua Dai · 1 shared paper, 2026 · strength 0.21
  22. Charles J. David · 1 shared paper, 2026 · strength 0.21
  23. Weibin Wang · 1 shared paper, 2026 · strength 0.21
  24. Yupei Zhao · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.